Skip to main content
Premium Trial:

Request an Annual Quote

Institut Pasteur Korea, Thermo Fisher to Co-Develop Drug Target-Identification Technology

Premium

Institut Pasteur Korea said this week that it has signed a deal with Thermo Fisher Scientific to co-develop RNAi reagents and services for use with the institute's PhenomicID genome-wide arrays for drug target identification.

Specific terms of the arrangement were not disclosed.

“Integrating … Thermo Scientific Dharmacon products and services with PhenomicID will provide an extremely effective plug-and-play solution for use in academic, biotech, and pharmaceutical labs for rapid identification of target compounds,” Devin Leake, director of research and development for genomics products at Thermo Fisher Scientific, said in a statement.